Description

The two leading vaccines approved to confront the COVID-19 pandemic were based on long-developed but never-before-approved mRNA and lipid nanoparticle delivery technology. As the world moves past the pandemic, this technology has many possibilities in therapeutic areas and markets, including other infectious diseases and indications. 

In this program, the expert panel will discuss the impact and future of mRNA technology, including a keynote address from Dr. Brett Leav from Moderna, who will discuss his experiences being on the front lines of the rollout of his company’s vaccine during the pandemic. In addition, the discussion will involve an overview of the landscape for RNA-based medicines beyond the COVID vaccines, critical intellectual property issues facing this market, and investments for breakthrough therapies. Following the overview, we will have an open moderated Q&A discussion where audience comments and questions will be essential to the conversation.

Join us for this timely overview of the mRNA markets and outlook for 2023 and beyond. 

REGISTER HERE